ProMetic Life Sciences Inc. has entered into definitive agreement with GENERIUM Pharmaceuticals for plasma-derived biopharmaceuticals to be manufactured and commercialized in Russia and Commonwealth of Independent States, or CIS. GENERIUM and ProMetic create global partnership for the co-development and commercialization of two plasma-derived coagulating factors. The strategic alliance includes the granting of manufacturing rights by ProMetic to GENERIUM for several plasma-derived biopharmaceuticals using ProMetic's proprietary PPPS technology.

In addition, ProMetic will provide training and technical support to manufacture said plasma-derived biopharmaceuticals in a facility to be built and operated by GENERIUM, in Russia. The design of the GENERIUM plasma purification facility will be based on ProMetic's own Laval facility and will have a plasma processing capacity of upto 600,000 litres per year. Construction of facility has already commenced and is expected to be completed by 2017.

GENERIUM will fully fund the construction and operating costs of its new cGMP PPPS facility. Once GENERIUM's plasma purification facility becomes operational, both GENERIUM's and ProMetic's facilities may complement each other as contract manufacturing organizations on specific biopharmaceutical products. ProMetic will also supply the required affinity resins for the PPPS based Russian facility and mid-single digit royalties will be paid by GENERIUM to ProMetic on sales of the biopharmaceutical products in the Russian /CIS markets.

The strategic alliance also includes two coagulation factors that will be co-developed and commercialized globally with both parties equally sharing net profits from sales.